Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
Alaunos Therapeutics (NASDAQ: TCRT) completed its acquisition of Velaris Therapeutics, a privately held biotech developing ActRII-Fc ligand traps and complementary biologics for pulmonary arterial hypertension and related cardiopulmonary diseases. Velaris' pipeline includes VLR199, VLR247, VLR258 and the anti-PDGF-B antibody VLR360, all discovered by Paragon Labs; the acquisition is the first company build supported by Paragon's newly expanded leadership team of former Apogee executives. No deal consideration or terms were disclosed in the release; additional information is in Alaunos' Form 8-K filed with the SEC on October 13, 2026.
Key figures
- Deal terms disclosed
- No
- Apogee acquisition value
- $10.9 billion (AbbVie's acquisition of Apogee, context only)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.